Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. [electronic resource]
Producer: 20000113Description: 1664-71 p. digitalISSN:- 0732-183X
- Adenocarcinoma -- drug therapy
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bone Neoplasms -- drug therapy
- Drug Resistance, Neoplasm
- Estramustine -- administration & dosage
- Etoposide -- administration & dosage
- Humans
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Prostatic Neoplasms -- drug therapy
- Quality of Life
- Soft Tissue Neoplasms -- drug therapy
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.